141 results
DEFA14A
VIR
Vir Biotechnology Inc
14 May 24
Additional proxy soliciting materials
4:05pm
as to whether the anticipated benefits of the Company’s collaborations with BARDA and other companies can be achieved; difficulties in collaborating
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
; the potential benefits, safety, and efficacy of Vir’s investigational therapies; and risks and uncertainties associated with drug development … the anticipated benefits of the BARDA collaboration can be achieved; unexpected safety or efficacy data or results observed during clinical trials or in data
8-K
EX-99.1
VIR
Vir Biotechnology Inc
18 Apr 24
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy
8:44am
trials, including the enrollment of
Vir’s clinical trials, and the expected timing of data readouts and presentations; the potential benefits, safety
8-K
EX-99.1
1vxfwfkey
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
S-3ASR
5ri37caw
3 Nov 23
Automatic shelf registration
4:33pm
S-3ASR
EX-4.5
oq0kcdlr3yju3h3xqff
3 Nov 23
Automatic shelf registration
4:33pm
S-3ASR
EX-4.6
f93f jl926d
3 Nov 23
Automatic shelf registration
4:33pm
S-3ASR
EX-1.2
79lsrh6
3 Nov 23
Automatic shelf registration
4:33pm
8-K
EX-99.1
f1gao2ccv9
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
mgxtu glvr
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
8-K
EX-99.1
wl06pr 0itafmlhzxcfq
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
61wtaa5
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am